Sarcoma News and Research

RSS

Apoptosis can reactivate latent herpesviruses in dying cell

Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology.

6 Sep 2013

Study: Apoptosis triggers alternate replication pathway in HHV

Washington, DC-Researchers from Children's National Medical Center have found that an alternate, "escape" replication process triggered by apoptosis-the process of cell death or "cell suicide"-appears to be common in human herpesviruses (HHV).

28 Aug 2013

Study reports racial, ethnic differences in incidence of soft tissue sarcomas in young adults, adolescents

Mei-Chin Hsieh, MSPH, CTR, of LSU Health Sciences Center New Orleans School of Public Health's Louisiana Tumor Registry, is the lead author of a study that reports racial and ethnic differences in the incidence of soft tissue sarcomas in adolescents and young adults.

26 Aug 2013

Researchers identify mechanism responsible for loss of tumor-suppressor gene in soft-tissue sarcomas

Researchers have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other soft-tissue sarcomas, rare cancers that strike mainly children and often respond poorly to treatment. Their cause is largely unknown.

8 Aug 2013

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.

26 Jul 2013

Four research teams receive NIH grants to explore use of genome sequencing in medical care

The National Institutes of Health has awarded four grants for up to four years to multidisciplinary research teams to explore the use of genome sequencing in medical care. The awards total approximately $6.7 million in the first year and, if funding remains available, approximately $27 million in total.

24 Jul 2013

Cedars-Sinai investigator awarded grant to study cell metabolism in childhood sarcomas

Sandra Orsulic, PhD, director of Women's Cancer Biology in the Women's Cancer Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, was awarded a $250,000 grant from Alex's Lemonade Stand Foundation to study cell metabolism in childhood sarcomas.

22 Jul 2013

Cedars-Sinai's first accredited Complex Surgical Oncology Fellowship program established

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has established the medical center's first accredited Complex Surgical Oncology Fellowship program, joining an elite group of 16 U.S. hospitals that have received accreditation for this type of training from the Accreditation Council for Graduate Medical Education, a premier evaluator of physician education programs.

22 Jul 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.

30 Jun 2013

Researchers to use $6.3M grant to develop novel therapeutic approaches for pediatric sarcomas

Researchers at Nationwide Children's Hospital will use a $6.3 million grant to further their study of pediatric sarcomas, a rare form of the disease that affects bone or soft tissue and accounts for 11 percent of all childhood cancers.

27 Jun 2013

Researchers discover promising new way to treat HIV-related blood cancer

Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

26 Jun 2013

CytRx reaches targeted enrollment in aldoxorubicin Phase 2b study for treatment of soft tissue sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced that it has reached the targeted enrollment of 105 evaluable patients in its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for soft tissue sarcoma.

25 Jun 2013

New plug-in optical sensor can help diagnose Kaposi's sarcoma

As antiretroviral drugs that treat HIV have become more commonplace, the incidence of Kaposi's sarcoma, a type of cancer linked to AIDS, has decreased in the United States.

5 Jun 2013

Researchers develop new mouse model to discover gene pathways that drive MPNST

University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral nerve sheath tumors that allow them to discover new genes and gene pathways driving this type of cancer.

21 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib.

8 May 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

Revised criteria improve early-onset dementia diagnosis

Updated diagnostic criteria based on the Frontotemporal Dementia Consensus are “encouragingly” sensitive and specific in identifying patients who have early-onset dementia, a study finds.

29 Apr 2013